Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise against tough blood cancers

NCT ID NCT04728893

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 8 times

Summary

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also checking for side effects. Participants take a tablet once a day, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nemtabrutinib (also called MK-1026 or ARQ 531), an oral tablet
What this could lead to
If successful, this could provide a new oral treatment option for people with certain blood cancers, helping to shrink tumors and control the disease.
What could go wrong
This is an early-phase (Phase 2) study, so the drug may not work as hoped or could cause serious side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 490 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment) * Has a life expectancy of at least 3 months, based on the investigator assessment * Has the ability to swallow and retain oral medication * Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Has adequate organ function * Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention * Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention * Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is \>350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART Part 1 and Part 2 (Cohorts A to C and J) * Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with * At least 2 lines of prior therapy (Part 1 only) * Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines * Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive * Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy * Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J * Has active disease for CLL/SLL clearly documented to initiate therapy * For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1) Part 2 (Cohorts D to G) \- Has a confirmed diagnosis of and meets the following prior therapy requirements: * Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D) * Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E) * Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen * Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G) * Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan * Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi * Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease * Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be \>15 mm in the longest diameter or \>10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10% * Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival Exclusion Criteria: * Has active HBV/HCV infection (Part 1 and Part 2) * Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen \<10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded * Has active central nervous system (CNS) disease * Has an active infection requiring systemic therapy * Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1 * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention * Has any clinically significant gastrointestinal abnormalities that might alter absorption * History of severe bleeding disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma follicular lymphoma hematopoietic and lymphoid system neoplasm Leukemia, B-Cell mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma Richter transformation Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukaemia Hematologic malignancies Non-hodgkins lymphoma Waldenstroms macroglobulinaemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    95 sites in 22 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)

    RECRUITING

    Bologna, 40138, Italy

  • ASST Spedali Civili di Brescia ( Site 1408)

    RECRUITING

    Brescia, 25123, Italy

  • Aalborg Universitetshospital ( Site 0703)

    RECRUITING

    Aalborg, North Denmark, 9000, Denmark

  • Aarhus University Hospital ( Site 0702)

    COMPLETED

    Aarhus N, Central Jutland, 8200, Denmark

  • Anhui Provincial Hospital ( Site 2808)

    ACTIVE_NOT_RECRUITING

    Hefei, Anhui, 230071, China

  • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)

    RECRUITING

    Ankara, 06590, Turkey (Türkiye)

  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)

    RECRUITING

    Calgary, Alberta, T2N 5G2, Canada

  • Astera Cancer Care ( Site 2732)

    RECRUITING

    East Brunswick, New Jersey, 08816, United States

  • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)

    ACTIVE_NOT_RECRUITING

    São Paulo, 01321-001, Brazil

  • Beaumont Hospital ( Site 2900)

    RECRUITING

    Dublin, Dublin 9, Ireland

  • Box Hill Hospital ( Site 0203)

    RECRUITING

    Box Hill, Victoria, 3128, Australia

  • Bristol Haematology and Oncology Centre ( Site 2610)

    RECRUITING

    Bristol, Bristol, City of, BS2 8ED, United Kingdom

  • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)

    RECRUITING

    A Coruña, La Coruna, 15006, Spain

  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • Centre Hospitalier Lyon-Sud ( Site 0804)

    RECRUITING

    Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)

    RECRUITING

    Nice, Alpes-Maritimes, 06202, France

  • Centre Hospitalier de Versailles ( Site 0809)

    COMPLETED

    Le Chesnay, Yvelines, 78150, France

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1431FWO, Argentina

  • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)

    RECRUITING

    Brasov, 500052, Romania

  • Chaim Sheba Medical Center ( Site 1302)

    RECRUITING

    Ramat Gan, 5262001, Israel

  • Colorado Blood Cancer Institute ( Site 2726)

    RECRUITING

    Denver, Colorado, 80218, United States

  • Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)

    COMPLETED

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76008, Ukraine

  • Debreceni Egyetem Klinikai Kozpont ( Site 1201)

    RECRUITING

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Dokuz Eylül Üniversitesi-Hematology ( Site 2402)

    ACTIVE_NOT_RECRUITING

    Izmir, 35340, Turkey (Türkiye)

  • FUNDALEU ( Site 0104)

    RECRUITING

    Caba, C1114AAN, Argentina

  • Fakultni nemocnice Hradec Kralove ( Site 0601)

    RECRUITING

    Hradec Králové, 500 05, Czechia

  • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)

    RECRUITING

    Brno, Brno-mesto, 625 00, Czechia

  • Fondazione IRCCS Policlinico San Matteo ( Site 1407)

    RECRUITING

    Pavia, 27100, Italy

  • Fudan University Shanghai Cancer Center ( Site 2801)

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)

    COMPLETED

    Mendoza, M5500AYB, Argentina

  • Fundacion Estudios Clinicos ( Site 0112)

    RECRUITING

    Rosario, Santa Fe Province, S2000DEJ, Argentina

  • GenesisCare - Cambridge ( Site 2611)

    RECRUITING

    Newmarket, Suffolk, CB8 7XN, United Kingdom

  • GenesisCare - Oxford ( Site 2607)

    RECRUITING

    Oxford, Oxfordshire, OX4 6LB, United Kingdom

  • GenesisCare - Windsor ( Site 2608)

    RECRUITING

    Windsor, England, SL4 3HD, United Kingdom

  • Guangxi Medical University Cancer Hospital ( Site 2814)

    RECRUITING

    Nanning, Guangxi, 530028, China

  • Ha Emek Medical Center ( Site 1305)

    RECRUITING

    Afula, 1834111, Israel

  • Hadassah Ein Karem Jerusalem ( Site 1300)

    RECRUITING

    Jerusalem, 9112001, Israel

  • Henan Cancer Hospital-hematology department ( Site 2802)

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Highlands Oncology Group ( Site 2728)

    RECRUITING

    Springdale, Arkansas, 72762, United States

  • Hopital Saint Louis ( Site 0805)

    RECRUITING

    Paris, 75010, France

  • Hospital Aleman ( Site 0102)

    RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1118AAT, Argentina

  • Hospital General Universitario de Alicante ( Site 2007)

    RECRUITING

    Alicante, 03010, Spain

  • Hospital Paulistano - Amil Clinical Research ( Site 0311)

    RECRUITING

    São Paulo, 01321-001, Brazil

  • Hospital Privado Universitario de Córdoba ( Site 0107)

    RECRUITING

    Córdoba, X5016KEH, Argentina

  • Hospital Puerta de Hierro ( Site 2009)

    RECRUITING

    Madrid, 28222, Spain

  • Hospital Universitari Vall d'Hebron ( Site 2001)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre ( Site 2003)

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario de Salamanca ( Site 2002)

    RECRUITING

    Salamanca, Castille and León, 37007, Spain

  • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)

    RECRUITING

    São Paulo, São Paulo, 05403-000, Brazil

  • Huashan Hospital, Fudan University ( Site 2821)

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Hunan Cancer Hospital ( Site 2822)

    RECRUITING

    Changsha, Hunan, 410013, China

  • IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)

    RECRUITING

    Reggio Emilia, 42123, Italy

  • IRCCS Ospedale San Raffaele ( Site 1402)

    RECRUITING

    Milan, 20132, Italy

  • Inselspital Bern ( Site 2303)

    RECRUITING

    Bern, Canton of Bern, 3010, Switzerland

  • Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)

    RECRUITING

    Lviv, Lviv Oblast, 79044, Ukraine

  • Institut Paoli-Calmettes ( Site 0803)

    RECRUITING

    Marseille, Bouches-du-Rhone, 13009, France

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)

    RECRUITING

    Tianjin, Tianjin Municipality, 301617, China

  • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)

    RECRUITING

    Rio de Janeiro, 20231-050, Brazil

  • Institutul Regional de Oncologie Iasi ( Site 1801)

    RECRUITING

    Iași, 700483, Romania

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)

    RECRUITING

    Naples, 80131, Italy

  • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)

    RECRUITING

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Istituto Tumori Giovanni Paolo II ( Site 1409)

    ACTIVE_NOT_RECRUITING

    Bari, 70124, Italy

  • Jewish General Hospital ( Site 0400)

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Jiangsu Province Hospital ( Site 2823)

    RECRUITING

    Nanjing, Jiangsu, 210029, China

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Kaplan Medical Center ( Site 1304)

    RECRUITING

    Rehovot, 76100, Israel

  • Liuzhou People's Hospital ( Site 2817)

    RECRUITING

    Liuzhou, Guangxi, 545006, China

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)

    COMPLETED

    Torrance, California, 90502, United States

  • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)

    ACTIVE_NOT_RECRUITING

    Cherkassy, Cherkasy Oblast, 18009, Ukraine

  • Mayo Clinic - Rochester ( Site 2706)

    ACTIVE_NOT_RECRUITING

    Rochester, Minnesota, 55905, United States

  • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)

    RECRUITING

    Spokane, Washington, 99208, United States

  • Mega Medipol-Hematology ( Site 2406)

    ACTIVE_NOT_RECRUITING

    Stanbul, Istanbul, 34214, Turkey (Türkiye)

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Institute ( Site 2507)

    RECRUITING

    Kyiv, 03022, Ukraine

  • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)

    COMPLETED

    Sydney, New South Wales, 2747, Australia

  • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)

    RECRUITING

    Nottingham, England, NG5 1PF, United Kingdom

  • Odense University Hospital ( Site 0705)

    COMPLETED

    Odense C, Region Syddanmark, 5000, Denmark

  • Orszagos Onkologiai Intezet ( Site 1200)

    RECRUITING

    Budapest, 1122, Hungary

  • Ovidius Clinical Hospital ( Site 1804)

    COMPLETED

    Ovidiu, Constanța County, 905900, Romania

  • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)

    RECRUITING

    Pécs, Baranya, 7624, Hungary

  • Peking University Third Hospital-Hematology ( Site 2827)

    RECRUITING

    Beijing, Beijing Municipality, 100191, China

  • Policlinico Umberto I ( Site 1404)

    COMPLETED

    Roma, 00161, Italy

  • Pratia MCM Krakow ( Site 1601)

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 30-727, Poland

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Rambam Medical Center ( Site 1301)

    RECRUITING

    Haifa, 3109601, Israel

  • Samsung Medical Center ( Site 2200)

    RECRUITING

    Seoul, 06351, South Korea

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)

    COMPLETED

    Fargo, North Dakota, 58102, United States

  • Sarah Cannon Research Institute UK ( Site 2612)

    RECRUITING

    London, London, City of, W1G 6AD, United Kingdom

  • Severance Hospital Yonsei University Health System ( Site 2201)

    RECRUITING

    Seoul, 03722, South Korea

  • Sir Charles Gairdner Hospital ( Site 0200)

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Sisli Florence Nightingale Hastanesi ( Site 2407)

    RECRUITING

    Istanbul, 34381, Turkey (Türkiye)

  • Sjaellands Universitetshospital Roskilde ( Site 0701)

    RECRUITING

    Roskilde, Region Sjælland, 4000, Denmark

  • Soroka Medical Center ( Site 1307)

    RECRUITING

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 1303)

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Spitalul Clinic Colțea ( Site 1805)

    RECRUITING

    Bucharest, Bucharest, 030171, Romania

  • St. Marien-Krankenhaus Siegen ( Site 0914)

    COMPLETED

    Siegen, North Rhine-Westphalia, 57072, Germany

  • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)

    RECRUITING

    Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400, Hungary

  • Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)

    COMPLETED

    Opole, Opole Voivodeship, 45-061, Poland

  • Szpitale Pomorskie Sp. z o.o. ( Site 1600)

    COMPLETED

    Gdynia, Pomeranian Voivodeship, 81-519, Poland

  • The Affiliated Hospital of Xuzhou Medical College ( Site 2818)

    ACTIVE_NOT_RECRUITING

    Xuzhou, Jiangsu, 221000, China

  • The Christie NHS Foundation Trust ( Site 2602)

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital of Nanchang University ( Site 2815)

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital, Zhejiang University ( Site 2826)

    RECRUITING

    Hangzhou, Zhejiang, 310002, China

  • The First Hospital of Jilin University-Hematology ( Site 2803)

    RECRUITING

    Changchun, Jilin, 130021, China

  • The Ottawa Hospital ( Site 0404)

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • The Royal Marsden NHS Foundation Trust. ( Site 2606)

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)

    ACTIVE_NOT_RECRUITING

    Chongqing, Chongqing Municipality, 400072, China

  • The Second Xiangya Hospital of Central South University ( Site 2820)

    RECRUITING

    Changsha, Hunan, 410011, China

  • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)

    COMPLETED

    Louisville, Kentucky, 40202, United States

  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)

    RECRUITING

    Dallas, Texas, 75390, United States

  • Universitaetsklinikum Carl Gustav Carus ( Site 0902)

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Koeln ( Site 0901)

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinikum Ulm. ( Site 0906)

    RECRUITING

    Ulm, Baden-Wurttemberg, 89081, Germany

  • University Hospital Limerick ( Site 2903)

    RECRUITING

    Limerick, V94 F858, Ireland

  • University of California San Diego Moores Cancer Center ( Site 2717)

    RECRUITING

    La Jolla, California, 92093-0698, United States

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)

    ACTIVE_NOT_RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-367, Poland

  • VKV Amerikan Hastanesi ( Site 2403)

    COMPLETED

    Istanbul, 34365, Turkey (Türkiye)

  • West China Hospital Sichuan University ( Site 2810)

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Wuhan Union Hospital ( Site 2816)

    RECRUITING

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.